Study summary
An ITK inhibitor gave durable responses with median survival over two years
37.5%response rate
What was tested
Soquelitinib, a pill blocking ITK, a signaling enzyme in T cells, for relapsed T-cell lymphoma after one to three earlier treatments.
What they found
- Response rate was 37.5% in people with one to three earlier treatments.
- Median overall survival was 28.1 months.
- Has FDA fast track and orphan designations.
What it means
Now in a phase 3 trial against standard choices.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.